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Abstract
Background: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in
malignant epithelial ovarian tumors, and associates with an unfavorable prognosis. To explore
possible contributors to the accumulation of hyaluronan, we examined the expression of
hyaluronan synthases (HAS1, HAS2 and HAS3) and hyaluronidases (HYAL1 and HYAL2), correlated
with hyaluronidase enzyme activity hyaluronan content and HAS1–3 immunoreactivity.
Methods: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups:
malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial
tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase
activity, hyaluronan staining, and HAS1–3 immunoreactivity in tissue sections of the same
specimens.
Results: The levels of HAS2 and HAS3 mRNA (HAS1 was low or absent), were not consistently
increased in the carcinomas, and were not significantly correlated with HAS protein or hyaluronan
accumulation in individual samples. Instead, the median of HYAL1 mRNA level was 69% lower in
grade 3 serous ovarian cancers compared to normal ovaries (P = 0.01). The expression of HYAL1,
but not HYAL2, significantly correlated with the enzymatic activity of tissue hyaluronidases (r = 0.5;
P = 0.006). An inverse correlation was noted between HYAL1  mRNA and the intensity of
hyaluronan staining of the corresponding tissue sections (r = -0.4; P = 0.025).
Conclusion: The results indicate that in serous epithelial ovarian malignancies HAS expression is
not consistently elevated but HYAL1 expression is significantly reduced and correlates with the
accumulation of hyaluronan. (233 words)
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Background
Because early-stage ovarian cancer produces nonspecific
symptoms, the majority of patients continue to present
with advanced disease, with limited chances of complete
surgical removal of the malignant tissue. The disease often
spreads by implantation through the mesothelial surfaces
covering the abdominal cavity. One of the suggested con-
tributors for this spreading is the CD44 receptor on cell
surface and its ligand, the extracellular matrix polysaccha-
ride hyaluronan [1,2]. We have found a 49-fold increase
in the median concentration of hyaluronan in grade 3
ovarian carcinomas, and an 89-fold increase in the corre-
sponding metastases compared to normal ovary. [3] This
is consistent with the fact that hyaluronan is an independ-
ent, unfavorable prognostic factor in epithelial ovarian
cancer [1], and suggests that hyaluronan is involved in the
progression of this, and other malignancies [4]. Blocking
the accumulation of hyaluronan might offer a new way of
fighting against the disease, and defining the causes of the
accumulation should provide means for this.
Hyaluronan can be produced in mammals by three
hyaluronan synthase isoenzymes: HAS1, HAS2 and HAS3
[5]. HAS mRNA levels often correspond to the rate of
hyaluronan synthesis, and are known to influence the
content of hyaluronan in transplanted tumors [6]. There-
fore, upregulation of HAS expression is a likely contribu-
tor to the hyaluronan accumulation in tissues, and
promotes tumor growth [7] and metastasis in experimen-
tal animals, in particular when coexpressed with hyaluro-
nidase [8].
The tissue content of hyaluronan is balanced by catabo-
lism, which is a more complex process [9]. Hyaluronan in
the extracellular matrix can be partially fragmented by
hyaluronidase activity or oxygen free radicals, and diffuse
away through lymph. Alternatively, hyaluronan can be
taken up by adjacent cells and be subject to lysosomal
degradation in the tissue of origin [10]. Therefore, the for-
mation of oxygen free radicals, access to lymph, local
uptake by cells, and hyaluronidases may each have a con-
tribution to the rate of hyaluronan catabolism. There are
6 hyaluronidases in the human genome, two of them
(HYAL1 and HYAL2) ubiquitous and characterized at pro-
tein level [9,11]. The major transcript of HYAL3 is enzy-
matically inactive and appears to have only a supportive
role in HYAL 1 expression [12]. HYAL 3 knockout mice
did not display any evidence of hyaluronan accumulation
[13]. Very little is known about HYAL4, but its expression
is limited, and it might be a chondroitinase rather than
hyaluronidase [11,14]. The expression of SPAM1-encoded
PH20 hyaluronidase is almost exclusively detected in tes-
tis and sperm, and shows activity in higher pH. We have
shown previously that ovarian tissues show no hyaluroni-
dase activity at pH 7 [3].
In an invasive bladder cancer cell line, blocking of HYAL1
expression decreases tumor growth, inhibits tumor infil-
tration and decreases microvessel density [15]. Increased
hyaluronidase expression has also been reported in colon
[9] and prostate cancer [16], as well as in breast tumor
metastases [17]. In contrast, experimental overexpression
of HYAL1 in a rat colon carcinoma cell line inhibits tumor
growth and generates necrotic tumors [6]. Recent findings
have suggested that depending on its concentration,
HYAL1 can function as a tumor promoter or as a suppres-
sor [16].
We started to determine the mechanism of hyaluronan
accumulation in ovarian cancer by analyzing the expres-
sion profiles of hyaluronan synthases and hyaluronidases
in a clinically defined set of tumors, and found that a sig-
nificantly decreased HYAL1  expression correlates with
lower hyaluronidase activity and elevated hyaluronan
content of the tumors, while HAS expression was not as
consistently associated to the accumulation of hyaluro-
nan.
Methods
Patients
39 ovarian tissue specimens from 39 patients were
divided into 5 groups: normal ovaries (n = 5), serous cys-
tadenomas (n = 10), serous borderline tumors (n = 4),
low grade (grades 1+2) (n = 10) and high grade (grade 3)
(n = 10) serous epithelial cystadenocarcinomas. The bor-
derline and malignant ovarian tumors were staged accord-
ing to FIGO (Table 1). The ethical committee of the
Table 1: Clinicopathological data of the epithelial ovarian tumor 
samples*
Tumor type (n)
Variable Malignant Borderline Benign
Age at diagnosis† 57 (43–83) 66 (20–82) 62 (16–72)
Histological type
Serous 20 4 10
Histological grade
13 ‡
27 ‡
31 0
FIGO stage
I2
II 1
III 13 2
IV 6
*In addition to the diseased tissues shown in the table, five samples of 
normal ovarian tissue were analysed
† medians (range)
‡ In this study grade I and grade II tumors were combined into one 
subgroupBMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
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Kuopio University Hospital has approved the study proto-
col and patients signed the informed consent.
Histology
Histological typing and grading was done according to the
WHO classification [18] 14. Grade 1 and 2 cancers were
combined into one subgroup.
Tissue samples
Tissue specimens collected in operation room were evalu-
ated and tumor sections were prepared by pathologist. All
the samples were collected and handled identically. Aliq-
uots of the tissues were 1) placed in RNAlater® (Ambion,
Austin, TX) for mRNA analyses; 2) fixed in 10% buffered
formalin and embedded in paraffin; and 3) homogenized
in 1 mM sodium EDTA containing 1 mM benzamidine-
HCl, 1 mM saccharic acid- 1,4-lactone, 1 mM β-mercap-
toethanol, 1 mM iodoacetate, and 0.5% Triton X-100,
clarified by centrifugation at 4°C (1,000 × g for 15 min
and 10,000 × g for 30 min) and the extracts stored at -
70°C until assayed.
RNA Extraction and cDNA Preparation
The samples were frozen by liquid nitrogen and pulver-
ized under pressure using a stainless steel cylinder and a
piston. Total RNA was isolated using Trizol® Reagent (Inv-
itrogen) according to manufacturer's protocol, quantified
spectrophotometrically and its integrity confirmed by aga-
rose electrophoresis, based on the appearance of the 18 S
and 28 S RNA bands. First strand cDNA was synthesized
from 2.5 μg of total RNA using High-Capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA) accord-
ing to manufacturer's protocol in a final volume of 50 μl.
Quantitative real-time RT-PCR
The PCR primers and fluorogenic probes for all target
genes (HYAL1,  HYAL2,  HAS1–3) and the endogenous
control HPRT1 (hypoxanthine phosphoribosyltransferase
1) were purchased as TaqMan® Gene Expression Assays
(Applied Biosystems). The assay numbers for these genes
were as follows: Hs00201046_m1 (HYAL1);
Hs00186841_m1 (HYAL2); Hs00758053_m1 (HAS1);
Hs00193435_m1 (HAS2); Hs00193436_m1 (HAS3);
Hs99999909_m1 (HPRT). The assays were supplied as a
20× Mix of PCR primers and TaqMan MGB (minor groove
binder) probes labeled with a 6-FAM dye and a non-fluo-
rescent quencher at the 3' end of the probe. The primers
were designed to span an exon-exon junction, eliminating
the possibility of detecting genomic DNA.
For each amplification, 6 μl of cDNA equivalent to 30 ng
of total RNA was mixed with 1 μl of 20 × Primer and
Probe Mix and 10 μl of 2 × TaqMan Universal Master Mix
in a final volume of 20 μl. Each sample was quantified
using standard curves that were established by 6 series of
4-fold serial dilution of cDNA obtained by reverse tran-
scription of 2.5 μg Universal Human Reference RNA
(Stratagene, La Jolla, CA). The standard curves and no-
template negative controls (NTC) were made on every
plate. Each sample and each point of the standard curve
was performed in triplicate reactions. The reactions were
performed in 96-well plates on the MX3000P real-time
instrument (Stratagene, La Jolla, CA). The PCR conditions
were as follows: 1 cycle at 95°C for 10 min, followed by
40 cycles of 95°C for 15 sec, 60°C for 1 min.
The HPRT1 gene we used for normalization is an accurate
reference for the quantitative gene expression assays in
clinical tumor samples [19]. Relative gene expression val-
ues were calculated as the ratio between the target gene
and HPRT1, obtained for each sample from the standard
curves. Finally, these values were divided by the mean
value of normal ovaries. CT values were used to roughly
compare the relative amounts of HYAL1  and  HYAL2
mRNAs.
Hyaluronidase assay
Hyaluronidase activities in the tissue extracts were deter-
mined by the release of biotinylated hyaluronan coupled
to the bottom of 96-well plates in triplicate reactions, as
previously described. The results were normalized to pro-
tein concentrations in the tissue extracts [3].
Staining of Hyaluronan
Deparaffinized 5-μm tissue sections were stained for
hyaluronan with our own preparation of biotinylated
hyaluronan-binding complex (bHABC) as described in
detail previously [1]. All samples were scored by an
observer unaware of the clinical data (M.A.) The percent-
age of tumor area with the strong intensity was estimated
using a continuous scale (0–100%), and used as an indi-
cator of hyaluronan accumulation.
Staining of HASs
Antigen retrieval was performed for HAS2 staining by
microwave treatment (700 W, 3 × 5 min) in citrate buffer.
Thereafter all deparaffinized sections were treated for 5
min with 1% H2O2  to block endogenous peroxidase,
washed with PB, and incubated in 1% bovine serum albu-
min (BSA) in PB for 30 min to block nonspecific binding.
Thereafter the sections were incubated overnight at 4°C
with polyclonal antibodies for HAS1 (1:100 dilution in
1% BSA, Santa Cruz Biotechnology, inc., Santa Cruz, CA),
HAS2 (1:50, Santa Cruz) or HAS3 (1:100, Santa Cruz),
followed by a 1 h incubation with biotinylated antigoat
antibody (1:1000, Vector Laboratories). The bound anti-
bodies were visualized with the avidin-biotin peroxidase
method (1:200, Vectastain Kit, Vector Laboratories). The
sections were incubated for 5 min in 0.05% diaminoben-
zidine (Sigma) and 0.03% hydrogen peroxide in PB. AfterBMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
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washes, the sections were counterstained with Mayer's
hematoxylin for 1 min, washed, dehydrated, and
mounted in DPX (Gurr, BDH Laboratory Supplies, Poole,
U.K.). The percentage of positive area for each HAS was
estimated in stroma and in epithelium for HAS1 and
HAS3. Staining intensity positivity of HAS2 in the epithe-
lium was estimated grading it into three categories: 1
(weak); 2 (moderate); and 3 (strong).
Statistical methods
Statistical analyses were carried out using SPSS 11.5 for
Windows (SPSS, Chigago, IL). Differences between
groups were first analysed by non-parametric Kruskal-
Wallis test, and when found significant were followed by
non-parametric Mann – Whitney U-test for paired com-
parisons between the patient groups. Also Chi-square test
were used to evaluate HAS2 epithelial staining. Correla-
tions between HAS3, HYAL1 and HYAL2 gene expression,
hyaluronidase activity, hyaluronan and HAS stainings
were analysed by the Spearman's correlation test.
Results
Hyaluronan content
The level of hyaluronan accumulation in the present set of
tumors was scored from tissue sections using a bioti-
nylated probe that specifically binds hyaluronan [1]. This
histological assay closely correlates with biochemical
quantitation of hyaluronan [3]. The content of hyaluro-
nan in the benign tumors was close to that of the normal
ovary, while the malignant tumors showed markedly
increased levels (malignant tumors vs. other lesions, P =
0.00026) (Fig. 1A).
Expression of HAS1 and HAS2
Since increased synthesis of hyaluronan often accounts
for hyaluronan accumulation, and since transcriptional
regulation seems to dominate the synthesis, mRNA from
these samples was analyzed by real-time RT-PCR for the
Figure 1
Hyaluronan content and HAS expression in human ovary and  its tumors Figure 1
Hyaluronan content and HAS expression in human 
ovary and its tumors. A) Strong hyaluronan staining inten-
sity (%) in NO (n = 4), SCA (n = 10), BL (n = 4), G1–2 (n = 
10) and G3 (n = 10) tissues. Relative mRNA levels of B) 
HAS2 and C) HAS3 in NO (n = 5), SCA (n = 10), BL (n = 4), 
G1+2 (n = 10) and G3 (n = 10) tissues. The boxes show the 
ranges between 25th and 75th percentiles, with a horizontal 
line at the median value. The whiskers extend to the 10th 
and 90th percentiles. The open circles represent the statisti-
cal outlier values. NO = normal ovary, SCA = serous cystad-
enoma, BL = serous borderline tumor, G1–2 = grade 1–2 
serous cystadenocarcinoma, G3 = grade 3 serous cystadeno-
carcinoma.BMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
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hyaluronan synthases HAS1,  HAS2, and HAS3. Tran-
scripts of HAS1 were detected at such a low level that reli-
able quantitation was not possible. The expression of
HAS2 was not markedly changed in benign and border-
line tumors (Fig. 1B). The median of HAS2 mRNA was
51–61% higher in the malignant tumors, compared with
normal ovaries, but the variance between individual
tumors was extensive (Fig. 1B). Overall, there were no sta-
tistically significant differences in HAS2 between the
groups (P = 0.387).
Expression of HAS3
The expression of HAS3 was more consistent, with signif-
icant differences between the subgroups (Kruskal-Wallis
test; P = 0.0084) (Fig 1C). Groupwise testing showed
increased HAS3 expression in benign tumors compared to
normal ovaries (median +60%, P = 0.0039). As compared
with normal ovaries, the median values of HAS3 in bor-
derline and grade 1+2 malignant tumors were not
changed, while grade 3 showed a trend for decline (-44%)
(Fig. 1C).
Hyaluronidase activity
The somewhat unexpected finding that the levels of HAS
mRNA were not consistently elevated in the tumors,
turned our attention to hyaluronidases. As noted before,
there is hyaluronidase activity at pH 3.7 in ovarian tissues,
with a tendency to decrease in malignant tumors [3]. In
the present material, the median values of hyaluronidase
activity in borderline and malignant tumors were indeed
58-40% lower than in normal ovary, but the difference
did not reach statistical significance (P = 0.076) (Fig. 2A).
Expression of HYAL1
Since two ubiquitous hyaluronidases, HYAL1 and HYAL2
were likely to account for the hyaluronidase activity, we
quantified their mRNA levels by real-time RT-PCR. There
was a gradual decline in HYAL1 expression from normal
ovaries through benign and borderline tumors down to
Figure 2
Hyaluronidase activity and HYAL1–2 expression in human  ovary and its tumors Figure 2
Hyaluronidase activity and HYAL1–2 expression in 
human ovary and its tumors. A) Hyaluronidase activity in 
NO (n = 4), SCA (n = 8), BL (n = 3), G1–2 (n = 8) and G3 (n 
= 9) tissues. Relative mRNA levels of B) HYAL1 and C) 
HYAL2 in NO (n = 5), SCA (n = 10), BL (n = 4), G1–2 (n = 
10) and G3 (n = 10). The boxes show the ranges between 
25th and 75th percentiles, with a horizontal line at the 
median value. The whiskers extend to the 10th and 90th per-
centiles. The open circles represent the statistical outlier val-
ues. NO = normal ovary, SCA = serous cystadenoma, BL = 
serous borderline tumor, G1–2 = grade 1–2 serous cystade-
nocarcinoma, G3 = grade 3 serous cystadenocarcinoma.BMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
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the cancers (Fig. 2B), with statistically significant differ-
ences between the groups (P = 0.022). A groupwise anal-
ysis indicated decreased HYAL1 in all non-benign tumors
compared to normal ovaries (borderline: -58% (median),
P = 0.05; grades 1+2: -79%, P = 0.05; grade 3: -69%, P =
0.01). The malignant grade 1+2 and grade 3 tumors
expressed also significantly less HYAL1  than benign
tumors (P = 0.034 and P = 0.028, respectively) (Fig. 2B).
Expression of HYAL2
The Kruskall-Wallis test indicated significant differences
also between the groups in HYAL2 expression (P = 0.033).
An increase of HYAL2  expression occurred in benign
tumors compared to normal ovaries (+76%, P = 0.037),
and while a decrease was noted in grade 3 cancers com-
pared to benign tumors (P = 0.0156) (Fig. 2C).
Relationship between hyaluronan accumulation and HAS 
and HYAL mRNA levels
No significant correlations were found between the level
of HAS2 or HAS3 mRNA and the hyaluronan content.
Instead, hyaluronidase activity showed a significant
inverse correlation with hyaluronan content (r = -0.5; P =
0.003). Furthermore, HYAL1 transcript levels correlated
with hyaluronan content (r = -0.4; P = 0.025) and
hyaluronidase activity (r = 0.5; P = 0.006, n = 32), suggest-
ing that HYAL1 dominated the differences in hyaluroni-
dase activity and contributed to the accumulation of
hyaluronan in the ovarian cancers.
Interestingly, HYAL2 did not correlate with hyaluronidase
activity, even though its mRNA level was 2–3 orders of
magnitude higher than that of HYAL1, as suggested by the
real-time RT-PCR assay. Despite their apparently diver-
gent changes in different tumor types, HYAL2 and HYAL1
mRNA levels still correlated positively with each other in
the whole patient material (r = 0.5; P = 0.0013).
HAS immunostainings
HAS1-positive cells were not present in any of the normal
specimens or in the stroma of cancers, but 41% of the can-
cer samples had a low percentage of HAS1 positive cancer
epithelial cells (Fig. 3) (Table 2). The percentage of the
HAS1 positive cells did not correlate with the mRNA lev-
els, hyaluronan or with the histological groups or grades.
Normal specimens showed no HAS3 signal but 46% of
the cancers presented generally low numbers of HAS3-
positive cancer epithelial cells (Fig. 3) (Table 2). An anal-
ysis including both normal and different tumor speci-
mens indicated that the proportion (%) of the HAS3-
positive cells of all epithelial cells correlated with hyaluro-
nan staining in the stroma (r = 0.424, p = 0.008), and neg-
atively with HYAL1 mRNA (r = -0.438, p = 0.005). HAS3
Distribution of HAS immunoreactivity in ovarian cancer Figure 3
Distribution of HAS immunoreactivity in ovarian 
cancer. Sections of ovarian cancer tissues were stained with 
antibodies against HAS1, HAS2 and HAS3, as indicated in the 
panels. The brown color indicates HAS, nuclei are stained 
with haematoxylin (blue). Note that HAS1 and HAS3 immu-
noreactivities reside mostly in the nests of the tumor epithe-
lial cells, while HAS2 is present also in the stromal cells. Scale 
bar 50 μm.BMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
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immunostainings did not correlate with the histological
type of specimens, or with tumor grade.
The anti-HAS2-antibody showed a more widespread
staining and, in contrast to HAS1 and HAS3 antibodies, it
stained both epithelial and stromal cells (Fig. 3) (Table 2).
In normal ovaries all epithelial cells showed weak HAS2
staining (Table 2). All tumor samples also showed HAS2
signal in the cancer epithelial cells, but the staining inten-
sity was more variable. In addition to samples with weakly
stained epithelial tissue similar to normal ovaries, 64% of
tumor samples showed a more intense epithelial HAS2-
immunostaining. The highest HAS2 staining intensities
were detected in benign tumors and in grade 1 carcinomas
(Table 2) and the intensities (graded into three categories)
was significantly different in the histological subgroups
(Chi-square P = 0.003). Of the stromal cells, 25–37%
were HAS2 positive both in normal ovaries and in tumor
specimens (Fig. 3) (Table 1) but the proportion of HAS2-
positive stromal cells did not correlate either with HAS2
mRNA level, hyaluronan staining intensity or histological
groups.
Discussion
Hyaluronan synthase (HAS) and hyaluronidase mRNA
levels were quantitated for the first time in ovarian cancers
and normal ovaries and benign tumors, and the results
correlated with hyaluronan and HAS immunocytochem-
istry in the corresponding tissue sections.
There was little HAS1 mRNA, no consistent upregulation
of HAS2 in the cancers, and the median values of HAS3
mRNA were actually lower in cancers than controls.
Immunohistochemical stainings of HAS proteins showed
a low level of HAS1, a slightly elevated level of HAS3 in
the tumor epithelia, and a variable elevation of HAS2
immunostaining in the tumor epithelial cells, in agree-
ment with the mRNA assays. In the stromal cells, no dif-
ference was observed with the HAS2 antibody in normal
and tumor samples, an unexpected result considering the
strong accumulation of hyaluronan in the same speci-
mens. Instead, HYAL1  expression was consistently
decreased in the cancers, with a concomitant trend to
reduced hyaluronidase enzyme activity.
HAS expression in ovarian cancer
Since  HAS2  and  HAS3  genes showed no consistent
increase in their expression in the serous ovarian cancers,
and  HAS1  mRNA was virtually absent, changes in the
transcriptional activity of the HAS genes seem not to be
the main factor in the increased hyaluronan content of
these tumors. A few of the samples showed high expres-
sion levels of HAS2, but most of the cancers showed no
elevation in the expression of any of the HAS genes.
Immunohistochemical stainings confirmed that the levels
of HAS1 and HAS3 were relatively low in ovarian cancers,
while the signal for HAS2 was more widespread, in line
with the real-time RT-PCR-analysis. While the stromal
cells were positive for HAS2, their staining intensity did
not correlate with that of stromal hyaluronan, nor with
the tumor type or grade. Unexpectedly, the HAS2 anti-
body stained also normal, benign and malignant ovarian
epithelial cells, all of which were largely negative with the
hyaluronan probe. Putting these findings together would
suggest that the epithelium somehow contributes to
hyaluronan mainly seen in the stroma. Theoretically, this
would be possible if the epithelial cells were unable to
hold and take up the synthesized hyaluronan by a recep-
tor like CD44. In support of this idea, the expression of
CD44 is reduced in the high grade ovarian cancers [20],
and the released hyaluronan could be trapped in the
stroma by complexing with versican [21]. Even if the epi-
thelial HAS contributes to stromal hyaluronan, it would
not explain the hyaluronan accumulation in the high
grade tumors since the epithelial HAS2 staining intensity
was highest in the benign and well differentiated tumors.
Table 2: Immunostaining of HAS1, HAS3 and HAS2 in human ovary and its tumors
HAS1 staining intensity* HAS3 staining intensity* HAS2 staining intensity
Stroma Epithelium Stroma Epithelium Stroma † Epithelium ‡
weak moderate strong
N o r m a l  O v a r y  ( n  =  5 ) 0000 3 7  ( 1 0  –  5 0 % ) 5 0 0
Benign (n = 10) 0 4 (1–5%) 0 4 (1–5%) 31 (10 – 50%) 0 5 5
Borderline (n = 4) 0 2 (5%) 0 1 (10%) 24 (10 – 25%) 1 2 1
Grade 1 + 2 (n = 10) 0 7 (5–50%) 0 6 (5–50%) 13 (10 – 25%) 3 4 3
Grade 3 (n = 10) 0 4 (1–10%) 0 7 (1–10%) 25 (10 – 50%) 6 4 0
Benign = serous cystadenoma, Borderline = serous borderline tumor
Grade 1–3 = serous epithelial cystadenocarcinoma
* num. of positive samples (% of positive cells), † mean % of positive cells (range), ‡ distripution of staining intensityBMC Cancer 2009, 9:143 http://www.biomedcentral.com/1471-2407/9/143
Page 8 of 9
(page number not for citation purposes)
Taken together, the data suggest that although in some of
the ovarian tumors a high HAS2/HAS3 level may contrib-
ute to hyaluronan accumulation, in the majority of cases,
particularly the high grade tumors, stromal hyaluronan
accumulation is not explained by the increased expression
of any of the HASs.
Relationship between HYAL1 and HYAL2
In terms of the cellular content of mRNA, the dominant
hyaluronidase in these tissues was HYAL2. However, the
fact that only HYAL1 mRNA correlated with the measured
hyaluronidase activity, and inversely with hyaluronan
accumulation, suggests higher enzymatic activity of
HYAL1 and more importance in hyaluronan catabolism.
It has been noted that HYAL2 preferentially produces
hyaluronan fragments above 20 kDa, while HYAL1 can
cut hyaluronan down to tetra- hexasaccharides [22], sug-
gesting that they either act in sequence in the degradation,
or have distinct functions related to the sizes of the end
products [9].
There was also a trend for low HYAL2 expression in the
most aggressive, grade 3 tumors, a result resembling that
in diffuse large B-cell lymphomas (DLBCLs) [23]. Like in
ovarian cancer, hyaluronidase activity in DCBCL tissue
extracts was not correlated with HYAL2 expression [23].
However, there was an inverse correlation between
HYAL2 expression and hyaluronan content [23]. Obvi-
ously, we need to know more about the distinct cellular
functions of HYAL1 and HYAL2 to define their exact roles
in malignancies.
Genomic changes in the HYAL genes
Allelic imbalance is frequent in the 3p21.3 chromosome
region containing HYAL1 and HYAL2 genes, suggesting
that this site is important in ovarian [24] and other can-
cers [9,11]. The positive correlation that still existed
between the expression of HYAL1  and HYAL2  may be
explained by concomitant deletions of these closely
mapped genes. Whether due to genomic alterations or
not, the present results suggest that hyaluronidase activity
contributes to the accumulation of hyaluronan, a known
promoter of malignant growth.
HYAL1 changes in ovarian vs. other cancers
The present findings of reduced HYAL1  expression are
consistent with those of another set of ovarian cancer
samples [3], but in a strong contrast to reports on prostate
and bladder tumors in which increased HYAL1 expression
in poorly differentiated tumors is associated with
advanced disease and unfavorable prognosis [15,16]. It
appears that malignancies arising from different cell types
utilize distinct strategies to survive and progress. Increased
hyaluronan may contribute to tumor growth and inva-
siveness by providing an expanded, loose matrix for can-
cer cells, protecting the tumor from immune reactions
and apoptosis, stimulating tumor cell migration, and
increasing cell proliferation [4]. While hyaluronidase may
block the above functions associated with high molecular
mass hyaluronan, it can at the same time create hyaluro-
nan oligosaccharides that stimulate neovascularization
[25], a crucial precondition for tumor expansion. The rel-
ative importance of the opposite roles of hyaluronidase
function in a particular type of cancer probably deter-
mines the outcome. The exact expression level is also
important; transfections of HYAL1 can either promote or
suppress malignant growth in a single cell type, depend-
ing on the resulting enzyme activity [16].
Possible mechanisms of HYAL-1 tumor suppressor function
High HYAL1 expression can result in apoptosis by increas-
ing the expression of WOX1 (WW domain-containing oxi-
doreductase, WWOX) [16]. WOX1 causes mitochondrial
permeabilization and is an essential partner of p53 in cell
death [26]. Importantly, WWOX variant 1 expression is
significantly lower in ovarian epithelial tumours than in
normal ovaries, which supports its role as a suppressor of
ovarian tumorigenesis [27]. Hyaluronidase can also cause
apoptosis by inducing NAD+-linked 15-hydroxyprostag-
landin dehydrogenase (15-PDGH), an enzyme that
degrades prostaglandins and promotes apoptosis in lung
carcinoma cells [28]. Furthermore, the high molecular
mass hyaluronan that occupies cell surface CD44 recep-
tors maintains p-Akt and PI3K dependent signals that pre-
vent cancer cell apoptosis, while hyaluronidase, and the
oligosaccharides created by hyaluronidase, block these
cell survival signals [29].
Conclusion
In conclusion, our results indicate for the first time that
decreased expression of HYAL1 rather than increased
expression of HAS1–3 correlates with the accumulation of
hyaluronan in serous ovarian cancer, and provides new
insight in the role of hyaluronidases in human cancer in
vivo.
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